Use of antihypertensives and the risk of Parkinson disease
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, CH-4031 Basel, Switzerland. Neurology
(Impact Factor: 8.29).
05/2008; 70(16 Pt 2):1438-44. DOI: 10.1212/01.wnl.0000303818.38960.44
Recent studies related angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers to possible neuroprotective effects. Little is known about neuroprotection of angiotensin II (AT II) antagonists or beta-blockers.
To explore the association between antihypertensive drug use and the risk of developing a first-time diagnosis of Parkinson disease (PD).
This was a case-control analysis within the UK-based General Practice Research Database. Cases were >or=40 years of age with an incident PD diagnosis between 1994 and 2005. We matched one control to each PD case on age, sex, general practice, index date, and duration of previous history in the database. We assessed antihypertensive drug use by timing and by exposure duration. We calculated ORs using conditional logistic regression, adjusted for body mass index, smoking, and various cardiovascular, metabolic, and psychiatric diseases and dementia.
We identified 3,637 cases with a first-time diagnosis of idiopathic PD and an equal number of matched controls. As compared to nonuse of antihypertensive drugs, the adjusted OR for current use of >or=30 prescriptions was 1.08 (95% CI 0.85 to 1.37) for ACE inhibitors, 0.91 (95% CI 0.41 to 2.00) for AT II antagonists, 1.16 (95% CI 0.95 to 1.41) for beta-blockers, and 0.77 (95% CI 0.63 to 0.95) for calcium channel blockers.
Current long-term use of calcium channel blockers was associated with a significantly reduced risk of a Parkinson disease diagnosis, while the risk was not materially altered for users of angiotensin converting enzyme inhibitors or beta-blockers and, with less statistical precision, for users of angiotensin II antagonists.
Available from: Michele Tagliati
- "Disease duration was not associated to increased risk of constipation, when corrected for age and pharmacological treatment. The percentage of PD patients taking beta-blockers in our cohort was in line with larger epidemiological studies  and their absolute number was sufficiently large to support the statistical conclusions. "
[Show abstract] [Hide abstract]
ABSTRACT: Constipation is one of most frequent non-motor symptoms of Parkinson's disease (PD) and it may precede the clinical diagnosis of PD by years, with negative effects on quality of life. In contrast to motor features, levodopa is ineffective and possibly detrimental on constipation. Treatment of constipation in PD is non-specific and frequently unsuccessful. Stemming from a clinical observation of unexpected relief of bothersome constipation, abdominal bloating and pain after treatment with the beta-blocker carvedilol in one patient, we have evaluated the association between the use of beta-blockers and the presence of constipation in a large, unselected PD cohort.
Retrospective review of the medical records of every patient with a diagnosis of PD seen in the Movement Disorders clinic at Cedars-Sinai Medical Center from October 2010 to April 2014.
341 medical records with a primary diagnosis of PD were reviewed, 336 of which contained information about constipation. Overall, 205/336 patients (61%) reported constipation. Among the 66 subjects treated with beta-blockers at the time of the encounter of record, only 28 (42.4%) reported constipation. By comparison, among the 270 subjects not treated with beta-blockers, 177 (65.5%) had constipation (χ(2) test p value = 0.001). Multivariate logistic analysis showed an odds ratio (OR) of 0.293 for beta-blockers (95% C.I. 0.161-0.535, p = 0.0001), 2.287 for levodopa (95% C.I. 1.271-4.117, p = 0.006) and 1.805 for dopamine agonists (95% C.I. 1.039-3.136, p = 0.036).
Beta-blockers are associated with a lower risk of constipation, while dopaminergic treatments appear to increase risk of constipation.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Available from: Birgit Liss
- "LTCC blockers are already well-established drugs, and are commonly prescribed to treat hypertension in clinical practice (Epstein et al., 2007; Exner et al., 2012; Coca et al., 2013). Indeed, retrospective epidemiological studies demonstrated that systemic administration of blood–brain-barrier permissive LTCC blockers of the DHP-type (like isradipine) reduce the relative risk for developing PD of about 30 % (Becker et al., 2008; Ritz et al., 2010; Simuni et al., 2010; Marras et al., 2012; Pasternak et al., 2012; Parkinson Study, 2013). However, reliable prospective studies are still missing, and not all epidemiologic studies report PD-protective effects of LTCC blockers (Ton et al., 2007; Louis et al., 2009; Simon et al., 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: Dopamine (DA) releasing midbrain neurons are essential for multiple brain functions, such as voluntary movement, working memory, emotion and cognition. DA midbrain neurons within the substantia nigra (SN) and the ventral tegmental area (VTA) exhibit a variety of distinct axonal projections and cellular properties, and are differentially affected in diseases like schizophrenia, attention deficit hyperactivity disorder, and Parkinson's disease (PD). Apart from having diverse functions in health and disease states, DA midbrain neurons display distinct electrical activity patterns, crucial for DA release. These activity patterns are generated and modulated by specific sets of ion channels. Recently, two ion channels have been identified, not only contributing to these activity patterns and to functional properties of DA midbrain neurons, but also seem to render SN DA neurons particularly vulnerable to degeneration in PD and its animal models: L-type calcium channels (LTCCs) and ATP-sensitive potassium channels (K-ATPs). In this review, we focus on the emerging physiological and pathophysiological roles of these two ion channels (and their complex interplay with other ion channels), particularly in highly vulnerable SN DA neurons, as selective degeneration of these neurons causes the major motor symptoms of PD.
Available from: Elena Fdez
- "Adult SNc DA neurons can compensate for L-type Ca2+ channel antagonism and continue pacemaking (Chan et al., 2007), and mice do not show obvious motor, learning, or cognitive deficits when treated with L-type Ca2+ channel antagonists (Bonci et al., 1998), suggesting that these compounds do not alter the functional activity of SNc DA neurons. Indeed, several studies in humans indicate that these compounds diminish the risk of developing PD (Becker et al., 2008; Ritz et al., 2010; Pasternak et al., 2012). However, they do not seem to slow progression of PD (Marras et al., 2012), maybe because of their relatively poor potency against Cav1.3 "
[Show abstract] [Hide abstract]
ABSTRACT: Parkinson's disease (PD) is a major health problem affecting millions of people worldwide. Recent studies provide compelling evidence that altered Ca(2) (+) homeostasis may underlie disease pathomechanism and be an inherent feature of all vulnerable neurons. The downstream effects of altered Ca(2) (+) handling in the distinct subcellular organelles for proper cellular function are beginning to be elucidated. Here, we summarize the evidence that vulnerable neurons may be exposed to homeostatic Ca(2) (+) stress which may determine their selective vulnerability, and suggest how abnormal Ca(2) (+) handling in the distinct intracellular compartments may compromise neuronal health in the context of aging, environmental, and genetic stress. Gaining a better understanding of the varied effects of Ca(2) (+) dyshomeostasis may allow novel combinatorial therapeutic strategies to slow PD progression.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.